Gene · 7307
Papers3,382
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 3,382
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. | Leukemia | 2024 | 37880479 | PubTator, text mining | PubMed |
| Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes. | Leuk Lymphoma | 2024 | 37865969 | PubTator, text mining | PubMed |
| Molecular measurable residual disease: staring at red herrings. | Haematologica | 2024 | 37584293 | PubTator, text mining | PubMed |
| Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor α in autoimmune hemolytic anemia and participate in Th17 polarization. | Haematologica | 2024 | 37534543 | PubTator, text mining | PubMed |
| Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia. | Haematologica | 2024 | 37345484 | PubTator, text mining | PubMed |
| IDH2 regulates U2AF1 expression and hydroxymethylation in MDS patients. | Biotechnol Genet Eng Rev | 2024 | 36942631 | PubTator, text mining | PubMed |
| Global proteomics insights for a novel small compound targeting the non-integrin Laminin Receptor in a macrophage cell model. | Front Drug Discov (Lausanne) | 2023 | 41970647 | PubTator, text mining | PubMed |
| Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing. | Contemp Oncol (Pozn) | 2023 | 38405213 | PubTator, text mining | PubMed |
| Multiple Genomic Alterations, Including a Novel AFF4::IRF1 Fusion Gene, in a Treatment-Refractory Blastic Plasmacytoid Dendritic-Cell Neoplasm: A Case Report and Literature Review. | Int J Mol Sci | 2023 | 38203475 | PubTator, text mining | PubMed |
| Venetoclax: A Game Changer in the Treatment of Younger AML Patients? | Cancers (Basel) | 2023 | 38201501 | PubTator, text mining | PubMed |
| High Mitochondrial Protein Expression as a Potential Predictor of Relapse Risk in Acute Myeloid Leukemia Patients with the Monocytic FAB Subtypes M4 and M5. | Cancers (Basel) | 2023 | 38201437 | PubTator, text mining | PubMed |
| Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab. | J Hematol | 2023 | 38188476 | PubTator, text mining | PubMed |
| [Clinical features of hemophagocytic lymphohistiocytosis associated with myeloid neoplasms: a report of 8 cases]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38185527 | PubTator, text mining | PubMed |
| Discovery of U2AF1 neoantigens in myeloid neoplasms. | J Immunother Cancer | 2023 | 38164756 | PubTator, text mining | PubMed |
| Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential. | Front Oncol | 2023 | 38162500 | PubTator, text mining | PubMed |
| SRSF7 downregulation induces cellular senescence through generation of MDM2 variants. | Aging (Albany NY) | 2023 | 38159247 | PubTator, text mining | PubMed |
| Polycythemia Vera: Barriers to and Strategies for Optimal Management. | Blood Lymphat Cancer | 2023 | 38146420 | PubTator, text mining | PubMed |
| Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape. | Int J Mol Sci | 2023 | 38139212 | PubTator, text mining | PubMed |
| Genetic Characteristics of Patients with Young-Onset Myelodysplastic Neoplasms. | J Clin Med | 2023 | 38137719 | PubTator, text mining | PubMed |
| Age-Related Alternative Splicing: Driver or Passenger in the Aging Process? | Cells | 2023 | 38132139 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7307/papers?page=14